只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 2026-06-01 2026-06-03 | REPL Replimune Group, Inc. | Sarchi Christopher Officer · Chief Commercial Officer | 卖出（S） | 12,000 | US$9.24 | US$110,880.00 | 180,962 | SEC |
| 2026-05-18 2026-05-20 | REPL Replimune Group, Inc. | Hill Emily Luisa Officer · Chief Financial Officer | 卖出（S） | 7,812 | US$5.08 | US$39,684.96 | 236,556 | SEC |
| 2026-05-18 2026-05-20 | REPL Replimune Group, Inc. | Patel Sushil Director,Officer · Chief Executive Officer | 卖出（S） | 37,324 | US$5.08 | US$189,605.92 | 747,492 | SEC |
| 2026-05-18 2026-05-20 | REPL Replimune Group, Inc. | Astley-Sparke Philip Director | 卖出（S） | 17,657 | US$5.08 | US$89,697.56 | 1,412,414 | SEC |
| 2026-05-18 2026-05-20 | REPL Replimune Group, Inc. | Sarchi Christopher Officer · Chief Commercial Officer | 卖出（S） | 8,626 | US$5.08 | US$43,820.08 | 192,962 | SEC |
| 2026-05-18 2026-05-20 | REPL Replimune Group, Inc. | Schwendenman Andrew Officer · Chief Accounting Officer | 卖出（S） | 7,894 | US$5.08 | US$40,101.52 | 107,057 | SEC |
| 2026-05-18 2026-05-20 | REPL Replimune Group, Inc. | Xynos Konstantinos Officer · Chief Medical Officer | 卖出（S） | 14,023 | US$5.08 | US$71,236.84 | 235,662 | SEC |
| 2026-04-21 2026-04-22 | RGEN REPLIGEN CORP | Loeillot Olivier Director,Officer · Chief Executive Officer | 卖出（S） | 3,832 | US$140.00 | US$536,480.00 | 54,246 | SEC |
| 2026-04-02 2026-04-06 | REPL Replimune Group, Inc. | Sarchi Christopher Officer · Chief Commercial Officer | 卖出（S） | 6,500 | US$8.01 | US$52,065.00 | 151,588 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| REPL | 8,604,331.9474 | 76,963 | 14,037,303.8563 | 61.30% | B, Q, N |